A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
- 31 December 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 95 (3) , 624-631
- https://doi.org/10.1016/j.ygyno.2004.08.028
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Is There a “Best” Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?Journal of Clinical Oncology, 2002
- Recurrent Ovarian Cancer: Evidence-Based TreatmentJournal of Clinical Oncology, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.Journal of Clinical Oncology, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell linesCancer Chemotherapy and Pharmacology, 1992
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990